Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages S47-S54

  Pincus, Theodore ^a   Richardson, Benjamin ^b   Strand, Vibeke ^c   Bergman, Martin J ^d  

^a RUSH MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c STANFORD UNIVERSITY   (United States)

^d DREXEL UNIVERSITY   (United States)

Author keywords

Clinical trials; Core Data Set measures; Joint counts; Patient questionnaires; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER;

ARTHRALGIA; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CORE DATA SET; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MUSCULOSKELETAL DISEASE ASSESSMENT; MUSCULOSKELETAL SYSTEM PARAMETERS; PATIENT GLOBAL ESTIMATE; PATIENT MONITORING; PHYSICIAN GLOBAL ESTIMATE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SWOLLEN JOINT COUNT; TENDER JOINT COUNT; ARTHRITIS, RHEUMATOID; BIOMECHANICS; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; HEALTH STATUS; HEALTH STATUS INDICATOR; JOINT; METABOLISM; MIDDLE AGED; PAIN MEASUREMENT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PREDICTIVE VALUE; PROCEDURES; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BIOMECHANICAL PHENOMENA; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CLINICAL TRIALS AS TOPIC; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; JOINTS; MIDDLE AGED; PAIN MEASUREMENT; PHYSICAL EXAMINATION; PREDICTIVE VALUE OF TESTS; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84922391820     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. FELSON DT, ANDERSON JJ, BOERS M et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36: 729-40.
2. CASTREJON I, MCCOLLUM L, TANRIOVER MD, PINCUS T: Importance of patient history and physical examination in rheumatoid arthritis compared to other chronic diseases: Results of a physician survey. Arthritis Care Res (Hoboken) 2012; 64: 1250-5.
3. PINCUS T, YAZICI Y, SOKKA T: Complexities in assessment of rheumatoid arthritis: absenof a single gold standard measure. Rheum Dis Clin North Am 2009; 35: 687-97, v.
4. ENGEL GL: The need for a new medical model: a challenge for biomedicine. Science 1977; 196: 129-36.
5. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
6. FELSON DT, SMOLEN JS, WELLS G et al.: American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573-86.
7. TUGWELL P, WELLS G, STRAND V et al.: Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000; 43: 506-14.
8. PINCUS T, ZELINGER D, BOLCE RJ, BAKER D: Relative efficiencies of 7 RA Core Data Set measures and 3 indices, DAS28 (Disease Activity Score), CDAI (Clinical Disease Activity Index) and RAPID3 (Routine Assessment of Patient Index Data), to distinguish infliximab from control treatments in the Attract and Aspire clinical Trials. Ann Rheum Dis 2009; 68: 551.
9. PINCUS T, AMARA I, SEGURADO OG, BERGMAN M, KOCH GG: Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol 2008; 35: 201-5.
10. WELLS G, LI T, MAXWELL L, MacLEAN R, TUGWELL P: Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 2008; 67: 260-5.
11. STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-50.
12. MAINI R, St CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
13. St CLAIR EW, van der HEIJDE DM, SMOLEN JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
14. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
15. KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
16. van de PUTTE LB, RAU R, BREEDVELD FC et al.: Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003; 62: 1168-77.
17. FURST DE, SCHIFF MH, FLEISCHMANN RM et al.: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563-71.
18. GENOVESE MC, BECKER JC, SCHIFF M et al.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353: 1114-23.
19. STRAND V, COHEN S, CRAWFORD B, SMOLEN JS, SCOTT DL, Leflunomide Investigators Groups: Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 640-7.
20. WARE JE, Jr., SHERBOURNE CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical care 1992; 30: 473-83.
21. WELSING PM, van GESTEL AM, SWINKELS HL, KIEMENEY LA, van RIEL PL: The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009-17.
22. ALETAHA D, SMOLEN J, WARD MM: Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 2784-92.
23. PINCUS T: The DAS is the most specific measure, but a patient questionnaire is the most informative measure to assess rheumatoid arthritis. J Rheumatol 2006; 33: 834-7.
24. SOKKA T, PINCUS T: Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: advantages and limitations. Rheum Dis Clin North Am 2009; 35: 713-22, v-vi.
25. SOKKA T, PINCUS T: Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission. J Rheumatol 2003; 30: 1138-46.
26. SOKKA T, PINCUS T: Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 2009; 36: 1387-90.
27. ABELSON B, SOKKA T, PINCUS T: Declines in erythrocyte sedimentation rates in patients with rheumatoid arthritis over the second half of the 20th century. J Rheumatol 2009; 36: 1596-9.
28. WOLFE F, PINCUS T: The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. J Rheumatol 2001; 28: 1817-24.
29. ANDERSON J, CAPLAN L, YAZDANY J et al.: Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012; 64: 640-7.
30. PINCUS T, YAZICI Y, BERGMAN MJ: Patient questionnaires in rheumatoid arthritis: advantages and limitations as a quantitative, standardized scientific medical history. Rheum Dis Clin North Am 2009; 35: 735-43, vii.
31. PINCUS T, BERGMAN MJ, YAZICI Y, HINES P, RAGHUPATHI K, MacLEAN R: An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physicianreported measures. Rheumatology (Oxford) 2008; 47: 345-9.
32. ALETAHA D, ALASTI F, SMOLEN JS: Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. Ann Rheum Dis 2014.
33. PINCUS T, SWEARINGEN CJ, BERGMAN MJ et al.: RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken) 2010; 62: 181-9.
34. COHEN SB, STRAND V, AGUILAR D, OFMAN JJ: Patient-versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. Rheumatology (Oxford) 2004; 43: 704-11.
35. PINCUS T, FURER V, KEYSTONE E, YAZICI Y, BERGMAN MJ, LUIJTENS K: RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken) 2011; 63: 1142-9.
36. STRAND V, SMOLEN JS, van VOLLENHOVEN RF et al.: Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patientreported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011; 70: 996-1002.
37. STRAND V, KOSINSKI M, GNANASAKTHY A, MALLYA U, MPOFU S: Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds. Health and quality of life outcomes 2014; 12: 31.
38. PINCUS T, CHUNG C, SEGURADO OG, AMARA I, KOCH GG: An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 2006; 33: 2146-52.
39. PINCUS T, HINES P, BERGMAN MJ, YAZICI Y, ROSENBLATT LC, MacLEAN R: Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials. J Rheumatol 2011; 38: 2565-71.
40. CASTREJON I, DOUGADOS M, COMBE B, GUILLEMIN F, FAUTREL B, PINCUS T: Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. J Rheumatol 2013; 40: 386-93.
41. PINCUS T, GIBSON KA, BERTHELOT JM:, Is a patient questionnaire without a joint examination as undesirable as a joint examination without a patient questionnaire? J Rheumatol 2014; 41: 619-21.
42. PINCUS T, WOLFE F: Patient questionnaires for clinical research and improved standard patient care: is it better to have 80% of the information in 100% of patients or 100% of the information in 5% of patients? J Rheumatol 2005; 32: 575-7.
43. PINCUS T, SKUMMER PT, GRISANTI MT, CASTREJON I, YAZICI Y: MDHAQ/RAPID3 Can provide a roadmap or agenda for all rheumatology visits when the entire mdhaq is completed at all patient visits and reviewed by the doctor before the encounter. Bull NYU Hosp Jt Dis 2012; 70: 177-86.